Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fuzuloparib - Jiangsu HengRui Medicine

Drug Profile

Fuzuloparib - Jiangsu HengRui Medicine

Alternative Names: Fluzoparib; HS-10160; SHR 3162

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; Jiangsu Hengrui Medicine Co.; Tianjin Medical University Cancer Institute and Hospital
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Phthalazines; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III HER2 negative breast cancer; Pancreatic cancer; Prostate cancer
  • Phase II Glioblastoma
  • Phase I/II Small cell lung cancer
  • No development reported Gastric cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Adjuvant therapy) in China (PO)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Neoadjuvant therapy) in China (PO)
  • 05 Dec 2023 Jiangsu HengRui Medicine completes a phase I trial for renal impairment in China (PO) (NCT05032235)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top